11.74
price up icon3.62%   0.41
after-market After Hours: 11.77 0.03 +0.26%
loading
Amicus Therapeutics Inc stock is traded at $11.74, with a volume of 1.96M. It is up +3.62% in the last 24 hours and up +10.75% over the past month. Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$11.33
Open:
$11.24
24h Volume:
1.96M
Relative Volume:
0.81
Market Cap:
$3.48B
Revenue:
$423.49M
Net Income/Loss:
$-147.07M
P/E Ratio:
-18.34
EPS:
-0.64
Net Cash Flow:
$-88.03M
1W Performance:
+2.18%
1M Performance:
+10.75%
6M Performance:
+12.88%
1Y Performance:
+1.38%
1-Day Range:
Value
$11.21
$11.75
1-Week Range:
Value
$11.21
$11.75
52-Week Range:
Value
$9.02
$14.57

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name
Name
Amicus Therapeutics Inc
Name
Phone
(215) 921-7600
Name
Address
3675 MARKET STREET, PHILADELPHIA, NJ
Name
Employee
517
Name
Twitter
@amicusrx1
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
FOLD's Discussions on Twitter

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-06-24 Initiated Jefferies Buy
May-30-24 Initiated Wells Fargo Overweight
May-14-24 Upgrade Guggenheim Neutral → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-09-22 Initiated Morgan Stanley Equal-Weight
Apr-13-22 Resumed Goldman Neutral
Jan-14-22 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-15-21 Upgrade Stifel Hold → Buy
Sep-30-21 Upgrade JP Morgan Neutral → Overweight
Jul-19-21 Resumed BTIG Research Buy
May-27-21 Initiated Needham Hold
May-21-21 Initiated UBS Buy
Apr-14-21 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-02-21 Initiated Stifel Hold
Feb-12-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-28-20 Resumed Cantor Fitzgerald Overweight
Dec-10-20 Downgrade Citigroup Buy → Neutral
Nov-11-20 Initiated Berenberg Hold
Jun-17-20 Initiated BTIG Research Buy
Feb-04-20 Resumed Cantor Fitzgerald Overweight
Nov-12-19 Reiterated H.C. Wainwright Buy
Jun-17-19 Initiated H.C. Wainwright Buy
Jun-05-19 Reiterated Cantor Fitzgerald Overweight
Apr-05-19 Initiated Janney Buy
Jan-30-19 Initiated Cantor Fitzgerald Overweight
Oct-29-18 Initiated Citigroup Neutral
Aug-17-18 Downgrade Chardan Capital Markets Buy → Neutral
Oct-06-17 Resumed Goldman Neutral
Sep-13-17 Reiterated Chardan Capital Markets Buy
Aug-10-17 Reiterated Chardan Capital Markets Buy
Jan-24-17 Upgrade Robert W. Baird Neutral → Outperform
May-18-16 Initiated BofA/Merrill Buy
Apr-14-16 Initiated Robert W. Baird Neutral
Apr-12-16 Reiterated Chardan Capital Markets Buy
Sep-16-15 Downgrade Chardan Capital Markets Buy → Neutral
Jun-16-15 Reiterated Chardan Capital Markets Buy
View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

pulisher
12:08 PM

Amicus Therapeutics Q3 2024 Earnings Preview - MSN

12:08 PM
pulisher
05:36 AM

Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

05:36 AM
pulisher
Nov 04, 2024

Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire

Oct 28, 2024
pulisher
Oct 26, 2024

Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance

Oct 25, 2024
pulisher
Oct 23, 2024

Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Pompe Disease Market on Track for Major Expansion by 2034, - openPR

Oct 22, 2024
pulisher
Oct 22, 2024

Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark - The Globe and Mail

Oct 22, 2024
pulisher
Oct 21, 2024

(FOLD) Proactive Strategies - Stock Traders Daily

Oct 21, 2024
pulisher
Oct 21, 2024

Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Oct 21, 2024
pulisher
Oct 21, 2024

Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America - Defense World

Oct 21, 2024
pulisher
Oct 19, 2024

How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Creative Planning Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Oct 19, 2024
pulisher
Oct 19, 2024

What is Zacks Research’s Estimate for FOLD Q3 Earnings? - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Teva settles patent litigation with Amicus (TEVA:NYSE) - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Zacks Research Issues Optimistic Outlook for FOLD Earnings - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

What is Zacks Research’s Estimate for FOLD Q2 Earnings? - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewswire

Oct 17, 2024
pulisher
Oct 17, 2024

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - Benzinga

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpHere's Why - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus announces settlement of Galafold patent litigation with Teva - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics settles patent litigation with Teva - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics settles patent litigation with Teva By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Shares Rise After Lawsuit Settlement, Deal With Teva - MarketWatch

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Oct 16, 2024
pulisher
Oct 15, 2024

Taking on analysts’ expectations and winning: Amicus Therapeutics Inc (FOLD) - SETE News

Oct 15, 2024
pulisher
Oct 15, 2024

Morgan Stanley Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $18.00 - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Amicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.com - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Gaucher’s Disease Treatment Industry to Witness an Outstanding Growth by 2034 |Amicus Therapeutics, Inc., Novartis AG, S – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Analyzing Amicus Therapeutics Inc (FOLD) After Recent Trading Activity - Knox Daily

Oct 14, 2024

Amicus Therapeutics Inc Stock (FOLD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):